(Total Views: 690)
Posted On: 12/17/2021 7:16:19 PM
Post# of 148878
Not much discussion of late, but long covid/PASC remains a serious condition with few options for those afflicted.
The coming omicron onslaught, even if less deadly as hoped, will provide another huge cohort of patients struggling to regain normalcy.
This longitudinal trial out of the U.K. paints a discouraging picture.
Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study
https://www.medrxiv.org/content/10.1101/2021....21267471v1
P3 Leronlimab trial cannot commence quickly enough.
The coming omicron onslaught, even if less deadly as hoped, will provide another huge cohort of patients struggling to regain normalcy.
This longitudinal trial out of the U.K. paints a discouraging picture.
Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study
https://www.medrxiv.org/content/10.1101/2021....21267471v1
Quote:
Findings 2320 participants have been assessed at five months after discharge and 807 participants have completed both five-month and one-year…... The proportion of patients reporting full recovery was unchanged between five months 501/165 (25.6%) and one year 232/804 (28.9%)
P3 Leronlimab trial cannot commence quickly enough.
(8)
(0)Scroll down for more posts ▼
